$IMNM
Immunome Inc.

2022 Q4 Form 10-Q Financial Statement

#000155837022017574 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.574M $3.329M $3.210M
YoY Change 3.32% 3.71% 174.36%
% of Gross Profit
Research & Development $4.213M $5.225M $4.513M
YoY Change -3.92% 15.78% 174.51%
% of Gross Profit
Depreciation & Amortization $95.00K $103.0K $286.0K
YoY Change -19.49% -63.99% 58.89%
% of Gross Profit
Operating Expenses $7.787M $8.534M $7.723M
YoY Change -0.73% 10.5% 174.06%
Operating Profit -$8.534M -$7.723M
YoY Change 10.5% 174.06%
Interest Expense $1.000K $1.000K -$3.000K
YoY Change -120.0% -133.33% -99.95%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $6.000K
YoY Change -100.0% -100.0% -99.89%
Pretax Income -$7.786M -$8.533M -$7.720M
YoY Change -0.84% 10.53% -7.88%
Income Tax
% Of Pretax Income
Net Earnings -$7.786M -$8.533M -$7.720M
YoY Change -0.84% 10.53% -7.84%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.65
Diluted Earnings Per Share -$0.64 -$0.75 -$646.9K
COMMON SHARES
Basic Shares Outstanding 12.13M 12.13M 11.81M
Diluted Shares Outstanding 12.13M 11.93M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.32M $27.08M $56.24M
YoY Change -58.72% -51.86% 734.47%
Cash & Equivalents $20.32M $27.08M $56.24M
Short-Term Investments
Other Short-Term Assets $2.326M $2.161M $4.947M
YoY Change -68.61% -56.32% 568.51%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.65M $29.24M $61.19M
YoY Change -60.01% -52.22% 717.72%
LONG-TERM ASSETS
Property, Plant & Equipment $681.0K $704.0K $961.0K
YoY Change -20.35% -26.74% -44.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $432.0K $432.0K $407.0K
YoY Change 0.0% 6.14% -84.69%
Total Long-Term Assets $1.397M $1.307M $1.368M
YoY Change 8.55% -4.46% -69.6%
TOTAL ASSETS
Total Short-Term Assets $22.65M $29.24M $61.19M
Total Long-Term Assets $1.397M $1.307M $1.368M
Total Assets $24.05M $30.55M $62.56M
YoY Change -58.49% -51.17% 422.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $3.139M $3.277M
YoY Change -22.0% -4.21% 24.74%
Accrued Expenses $4.931M $4.230M $4.472M
YoY Change -25.86% -5.41% 91.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $16.00K
YoY Change -94.75%
Total Short-Term Liabilities $7.331M $7.369M $7.765M
YoY Change -24.64% -5.1% 43.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $62.00K $93.00K $0.00
YoY Change 416.67% -100.0%
Total Long-Term Liabilities $62.00K $93.00K $0.00
YoY Change 416.67% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.331M $7.369M $7.765M
Total Long-Term Liabilities $62.00K $93.00K $0.00
Total Liabilities $7.393M $7.462M $7.765M
YoY Change -24.1% -3.9% -38.85%
SHAREHOLDERS EQUITY
Retained Earnings -$116.0M -$108.2M -$71.30M
YoY Change 46.64% 51.75% 41.75%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.65M $23.08M $54.79M
YoY Change
Total Liabilities & Shareholders Equity $24.05M $30.55M $62.56M
YoY Change -58.49% -51.17% 422.06%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$7.786M -$8.533M -$7.720M
YoY Change -0.84% 10.53% -7.84%
Depreciation, Depletion And Amortization $95.00K $103.0K $286.0K
YoY Change -19.49% -63.99% 58.89%
Cash From Operating Activities -$6.683M -$7.571M -$4.145M
YoY Change -1.79% 82.65% 63.83%
INVESTING ACTIVITIES
Capital Expenditures $72.00K $0.00 -$26.00K
YoY Change -614.29% -100.0% -78.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$72.00K $0.00 -$26.00K
YoY Change 414.29% -100.0% -78.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 585.0K
YoY Change -100.0% -100.0% -246.25%
NET CHANGE
Cash From Operating Activities -6.683M -7.571M -4.145M
Cash From Investing Activities -72.00K 0.000 -26.00K
Cash From Financing Activities 0.000 0.000 585.0K
Net Change In Cash -6.755M -7.571M -3.586M
YoY Change -3.69% 111.13% 17.57%
FREE CASH FLOW
Cash From Operating Activities -$6.683M -$7.571M -$4.145M
Capital Expenditures $72.00K $0.00 -$26.00K
Free Cash Flow -$6.755M -$7.571M -$4.119M
YoY Change -0.53% 83.81% 70.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12127501
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11934491
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12125947
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11348856
dei Entity Central Index Key
EntityCentralIndexKey
0001472012
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12127594
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12110373
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
200000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39580
dei Entity Registrant Name
EntityRegistrantName
Immunome, Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
321-3700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
IMNM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12128843
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27078000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2161000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
29239000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
56638000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
704000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
855000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
171000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q3 us-gaap Deferred Costs
DeferredCosts
332000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108215000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79105000
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2022Q3 us-gaap Assets
Assets
30546000
CY2021Q4 us-gaap Assets
Assets
57925000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3139000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3077000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4230000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7369000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9728000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
93000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12000
CY2022Q3 us-gaap Liabilities
Liabilities
7462000
CY2021Q4 us-gaap Liabilities
Liabilities
9740000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12127594
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12110373
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131298000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127289000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
23084000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30546000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57925000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5225000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4513000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19020000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9725000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3309000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3210000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10094000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7635000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8534000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
7723000
us-gaap Operating Expenses
OperatingExpenses
29114000
us-gaap Operating Expenses
OperatingExpenses
17360000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8534000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7723000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29114000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17360000
CY2021Q3 us-gaap Other Income
OtherIncome
6000
us-gaap Other Income
OtherIncome
506000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-3000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8533000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7720000
us-gaap Net Income Loss
NetIncomeLoss
-29110000
us-gaap Net Income Loss
NetIncomeLoss
-16859000
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
622000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
622000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9155000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7720000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29732000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16859000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12127501
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11934491
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12125947
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11348856
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30277000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1340000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8533000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
23084000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3977000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
us-gaap Net Income Loss
NetIncomeLoss
-29110000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
23084000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
60617000
CY2021Q3 imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
262000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1155000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
432000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7720000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
54793000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
559000
imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
26666000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2229000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1338000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
74000
us-gaap Net Income Loss
NetIncomeLoss
-16859000
us-gaap Profit Loss
ProfitLoss
-29110000
us-gaap Profit Loss
ProfitLoss
-16859000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22151000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
327000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16477000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
54793000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27178000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56343000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
74000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1338000
imnm Payment Of Offering Costs
PaymentOfOfferingCosts
18000
imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
97000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27963000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
637000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
44000
us-gaap Share Based Compensation
ShareBasedCompensation
3977000
us-gaap Share Based Compensation
ShareBasedCompensation
2229000
imnm Deferred Rent
DeferredRent
-8000
imnm Forgiveness Of Ppp Loan
ForgivenessOfPppLoan
-500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5236000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1819000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
62000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2088000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-2471000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2811000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-72000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22007000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11421000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
176000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-176000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-65000
imnm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27225000
imnm Payments Of Common Stock And Warrants Issuance Costs
PaymentsOfCommonStockAndWarrantsIssuanceCosts
559000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
215000
imnm Stock Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities Current
StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilitiesCurrent
289000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
us-gaap Net Income Loss
NetIncomeLoss
-29100000
us-gaap Net Income Loss
NetIncomeLoss
-16900000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108200000
CY2021Q4 imnm Shares Authorized For Issuance Amount
SharesAuthorizedForIssuanceAmount
200000000.0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27100000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the expected volatility used to estimate fair value of stock options and accrued research and development expenses. Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27078000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27178000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56343000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56243000
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3812871
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3250769
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2020Q1 imnm Refundable Employee Retention Credit
RefundableEmployeeRetentionCredit
800000
CY2022Q3 imnm Contra Expenses
ContraExpenses
0.0
imnm Contra Research And Development Expense
ContraResearchAndDevelopmentExpense
600000
imnm Contra General And Administrative Expense
ContraGeneralAndAdministrativeExpense
200000
imnm Contra Expenses
ContraExpenses
0
CY2021Q3 imnm Contra Expenses
ContraExpenses
0
CY2022Q3 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
800000
CY2021Q4 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
0.0
CY2022Q3 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
847000
CY2022Q3 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
530000
CY2021Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
586000
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
324000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
492000
CY2022Q3 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
243000
CY2021Q4 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
2674000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
217000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2019000
CY2021Q4 imnm Unbilled Reimbursement Receivable Current
UnbilledReimbursementReceivableCurrent
1638000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2161000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2022Q3 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2514000
CY2021Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2840000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1367000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1246000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
236000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
91000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000
CY2022Q3 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
22000
CY2021Q4 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
2021000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4230000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2021Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q3 imnm Collaborative Arrangements Product Development And Regulatory Approval Milestone Payments Payable
CollaborativeArrangementsProductDevelopmentAndRegulatoryApprovalMilestonePaymentsPayable
2600000
CY2022Q3 imnm Collaborative Arrangements Commercial Milestone Payments Payable
CollaborativeArrangementsCommercialMilestonePaymentsPayable
1500000
CY2022Q3 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
0.0
imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
100000
imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
0
CY2021Q3 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
22042
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.20
imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14115
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
15.94
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
600000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
634
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1340000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1155000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3977000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2229000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.856
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.831
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
CY2022Q3 imnm Fair Value Of Common Stock
FairValueOfCommonStock
3.64
CY2021Q3 imnm Fair Value Of Common Stock
FairValueOfCommonStock
23.61
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2005756
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.26
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
543900
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.64
imnm Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P9Y5M12D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
17.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
17221
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.85
imnm Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
P7Y4M2D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2509759
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1111573
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M28D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3400000

Files In Submission

Name View Source Status
0001558370-22-017574-index-headers.html Edgar Link pending
0001558370-22-017574-index.html Edgar Link pending
0001558370-22-017574.txt Edgar Link pending
0001558370-22-017574-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tmb-20220930_def.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220930.xsd Edgar Link pending
tmb-20220930x10q.htm Edgar Link pending
tmb-20220930xex31d1.htm Edgar Link pending
tmb-20220930xex31d2.htm Edgar Link pending
tmb-20220930xex32d1.htm Edgar Link pending
tmb-20220930xex32d2.htm Edgar Link pending
tmb-20220930_cal.xml Edgar Link unprocessable
tmb-20220930x10q_htm.xml Edgar Link completed
tmb-20220930_pre.xml Edgar Link unprocessable
tmb-20220930_lab.xml Edgar Link unprocessable